The CE approval opens Europe for Cornerstone Robotics as the company expands its global surgical robotics business
Updated
May 29, 2026 4:20 AM
A tray of surgical tools. PHOTO: UNSPLASH
As surgical robotics companies expand beyond domestic markets, regulatory approvals are becoming a critical part of global growth. Companies are no longer competing only on hardware and clinical performance. They are also competing on their ability to enter tightly regulated healthcare systems and build long-term hospital partnerships.
Hong Kong-based Cornerstone Robotics is now moving further into that phase of expansion after its Sentire Endoscopic Surgical System received CE Mark certification under the European Union’s Medical Device Regulation framework.
The approval allows the company to commercialize the system across European markets for minimally invasive procedures in general surgery, gynecology, thoracic surgery and urology. For surgical robotics companies, regulatory approvals often represent more than product validation. They also determine market access, hospital adoption opportunities and long-term commercial scale.
Cornerstone Robotics has already been building clinical operations in the UK ahead of the approval. Since 2025, the company has worked with Portsmouth Hospitals University NHS Trust on clinical investigations involving the Sentire Surgical System. According to the company, the system has been used across procedures involving urology, gynecology and gastrointestinal surgery. The company says the clinical investigation helped generate real-world data to support physician training, research and future adoption efforts.
Alongside the regulatory approval, Cornerstone Robotics is also expanding its local operations in Europe. The company established a UK subsidiary in 2025 and has been developing training, clinical support and after-sales service capabilities for hospitals using the system.
That operational buildout reflects a larger challenge inside surgical robotics. Hospitals adopting robotic systems often require ongoing clinical training, technical support and workflow integration alongside the hardware itself.
Cornerstone Robotics says its strategy centers around vertically integrated development across engineering, software, imaging and robotics systems. The company argues that this structure gives it greater control over product development, supply chain management and long-term operational stability.
Professor Samuel Au, Founder and CEO of Cornerstone Robotics, said: "Receiving CE Certification marks a major milestone in Cornerstone Robotics' evolution from a technology innovator to a global clinical solutions provider. From our first clinical investigation in Portsmouth, UK, to achieving European regulatory approval, each step of the journey reflects our commitment to proprietary innovation, product excellence, and clinical value. Looking ahead, we will continue expanding into key global markets and partnering with leading medical institutions to bring high-quality surgical robotic solutions to more physicians and patients worldwide."
The CE approval also comes several months after the company completed an oversubscribed financing round of approximately US$200 million in November 2025.
The funding and regulatory expansion together signal how surgical robotics companies are increasingly entering a more commercially focused stage of growth. Beyond research and development, companies are now investing more heavily in regulatory approvals, hospital partnerships, physician training and international operational infrastructure as competition expands across global healthcare markets.
Keep Reading
A Massachusetts startup advances scalable light-control tech for AR, AI and imaging markets
Updated
March 17, 2026 1:01 AM
Myrias Optics' Nanoimprinted All-inorganic Metaoptic. PHOTO: MYRIAS OPTICS
Myrias Optics, a Massachusetts-based optical technology startup, has raised US$2.1 million in a Seed 1 financing round to accelerate the commercialization of its advanced light-control technology. The round was led by MassVentures, with participation from existing investors Hoss Investment Inc., Maroon Venture Partners and Tenon Venture Partners, as well as new investors Mill Town Capital, TiE Boston Angels and Doug Crane. This new round follows a US$3.3 million seed financing completed in December 2023, led by Asia Optical, and a US$1.5 million Direct-to-Phase II award from the National Science Foundation. In total, Myrias has secured US$6.9 million to date, positioning it to move from development to scaled production.
The company builds ultra-thin, nano-patterned surfaces that precisely control how light moves through a device. These structures replace or enhance traditional lenses and optical parts inside products such as augmented reality headsets, AI data center hardware, consumer electronics, industrial systems and medical imaging devices. The goal is straightforward: to deliver high optical performance while making the parts easier and more cost-effective to manufacture in large quantities.
Across industries such as augmented reality and AI infrastructure, manufacturers face a common challenge. They need highly precise light-guiding components that can withstand heat and long-term use. At the same time, those components must be produced consistently and at scale. Traditional semiconductor-style fabrication can be costly, while polymer-based optical manufacturing can face limits in durability and thermal stability.
Myrias addresses this gap by using inorganic materials and a nanoimprint manufacturing process to create stable, repeatable optical layers on wafers. This approach is designed to combine performance with manufacturability. In augmented reality systems, for example, the company’s technology enables higher viewing angles while remaining suitable for volume production. In AI data centers, the same material and process advantages support improved light transfer and stronger performance under demanding thermal conditions. These benefits also extend to advanced imaging systems in consumer, industrial and medical markets.
The new Seed 1 funding is intended to expand manufacturing capacity and scale pilot production lines. The company will also continue executing active customer programs. Myrias is already working with strategic partners and Tier 1 supply chain participants to integrate its waveguide and light-shaping solutions into commercial AR platforms, AI photonics systems and advanced imaging products. The capital, therefore, supports a clear next step: moving from validated prototypes to a steady commercial supply.